5-[3-Methoxy-4-(4-methoxy-benzyloxy)-benzyl]-pyrimidine-2,4-diamine

GW-2580 (870483-87-7) is a potent and selective inhibitor of cFMS receptor kinase. Completely inhibits cFMS in vitro at 60 nM with no activity against 26 other kinases1. Completely inhibits CSF-1 induced growth of mouse M-NFS-60 myeloid cells and human monocytes (at 1 μM)1. GW-2580 completely inhibits bone degradation in human osteoclasts, rat calvaria and fetal long bone1. Inhibits LPS-induced TNF production in mice. GW-2580 abrogates infiltration of macrophages into synovial joints of arthritic mice2. Active in vivo.

GW2580 has been used to study its effect on paracrine signaling from stretched cardiomyocyte on cardiac fibroblast phenotype.

GW2580 is a cell-permeable, potent and selective ATP-competitive inhibitor of cFMS kinase, receptor for macrophage-colony stimulating factor, M-CSF or CSF-1, and a key regulator of macrophage and osteoclast activation and differentiation. FMS is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony-stimulating factor (M-CSF or CSF-1). Overexpression of CSF-1 and/or FMS has been implicated in a number of disease states including the growth of metastasis of some types of cancer, in promoting osteoclast proliferation in bone osteolysis, and in several inflammatory disorders. GW2580 selectively inhibits cFMS-mediated cellular functions in vitro at 0.06 μM as well as CSF-1-dependent tumor growth in vivo. GW2580 was inactive against 26 other kinases.

Store at -20°C

1) Conway et al. (2005), Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580; Proc. Natl. Acad. Sci. USA, 102 16078 2) Paniagua et al. (2010), c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis; Arthritis Res. Ther., 12 R32